Pediatric eosinophilic esophagitis treatment pathways

Pediatric eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder causing eosinophilic inflammation and impaired esophageal function. Treatment in children must balance symptom control, safe swallowing, nutrition and growth while preventing fibrostenotic complications.

Presentation changes with age: infants may feed poorly, toddlers refuse textures, and older children develop dysphagia, vomiting, abdominal pain or food impaction. Refractory symptoms deserve assessment beyond routine reflux management, particularly when feeding difficulty persists despite appropriate acid suppression.

Current algorithms are sequential rather than rigid. They establish the diagnosis and severity, trial an inexpensive first treatment, escalate according to response and family preference, then reassess symptoms, histology and nutritional status. Shared decisions matter because dietary restriction and endoscopy carry different burdens.

ISDE 2021 brought these questions into its scientific sessions, workshops and abstract discussions. International evidence still needs translation for Australian practice, where referral access, medicine subsidy, specialist dietetics and family geography shape what can be delivered.

Confirming disease and defining severity

Diagnosis requires evidence of esophageal dysfunction and eosinophilia, usually at least 15 eosinophils per high-power field on endoscopy with biopsies. Consider other causes of esophageal eosinophilia, but a failed proton pump inhibitor (PPI) response is no longer required to diagnose EoE.

Before treatment, document weight, growth, feeding behavior, atopy, swallowing impairment and quality of life. Endoscopy should assess edema, furrows, exudates, rings and strictures, with biopsies from several esophageal levels because inflammation can be patchy.

Starting with acid suppression

A supervised four-to-eight-week PPI trial is a reasonable first option for many children with dysphagia or suspected reflux. Use an age-appropriate regimen, document adherence and reassess symptoms and feeding safety; symptom improvement does not guarantee histologic remission.

If symptoms, growth or inflammation remain unacceptable, move to structured dietary elimination. Choose the restriction level according to likely allergens, disease burden, cooking, cost, school needs and nutritional reserves. Children unable to maintain oral intake need prompt review for dehydration, nutrition and airway protection.

Selecting a dietary elimination pathway

Empiric elimination avoids relying on skin-prick or specific IgE results, which do not reliably identify all food triggers. Dietitians should choose the restriction level, provide nutrient-equivalent substitutions and plan reintroduction, so remission can be confirmed without prolonged nutritional deficiency.

Australian supermarkets make milk and wheat elimination manageable, but specialty gluten-free, low-allergen and elemental products can be costly and inconsistently stocked. Dietetic services in Melbourne, Sydney, Brisbane and Perth can support substitution planning; regional families may need telehealth and clear formula storage instructions.

Escalating beyond proton pump inhibitors

Swallowed topical corticosteroids, commonly budesonide or fluticasone delivered with a spacer, can reduce inflammation when diet and PPIs are insufficient. In Australia, EoE use is generally off-label, so discuss candidiasis, inhaler technique and systemic steroid risks. Balloon dilation may be needed for a fixed narrowing, but complements rather than replaces anti-inflammatory treatment.

Dupilumab, an IL-4/IL-13 biologic, offers escalation for selected patients with persistent disease, subject to Australian age, regulatory and funding criteria. It may reduce inflammation and dysphagia without dietary restriction, yet specialist oversight and continued monitoring are needed because response varies and relapse can follow treatment withdrawal.

Monitoring control and relapse

Monitoring should combine symptoms with growth, nutrition, feeding safety and objective inflammation. Repeat endoscopy with biopsies may be needed because symptom relief does not reliably reflect histologic remission. Aim for both clinical improvement and, when feasible, fewer than 15 eosinophils per high-power field.

Relapse is common when an effective diet or medication is stopped without a plan. Maintain the successful strategy, then step down only after sustained control. Use planned food reintroduction to identify triggers, and record school absences, anxiety around eating, growth and caregiver workload alongside laboratory and endoscopic findings.

Adapting care to the Australian system

Australian care spans public hospitals, private gastroenterology and multidisciplinary allergy services. Referral access, endoscopy waiting times and dietetic capacity vary across Melbourne, Sydney, Brisbane, Perth and regional centers; severe feeding disorders may require escalation to a tertiary pediatric service. Teleconference reviews can reduce travel burdens.

Medicare and the Pharmaceutical Benefits Scheme can reduce costs when current criteria are met, while off-label swallowed steroids, elimination foods and specialized formula may remain out-of-pocket. Families importing nutrition products or medicines should check Australian-approved status, customs clearance and storage requirements. ISDE 2021’s virtual format also illustrates how virtual congress delivery can support continuing education for clinicians unable to travel.

Making the plan work for children

Families should help choose among dietary, topical steroid and biologic strategies after receiving clear information about benefits, risks and logistics. Written school plans, practical food lists, regular growth review and access to a psychologist or feeding therapist can reduce treatment-related strain.

A shared care plan should identify who reviews symptoms, medication, diet and endoscopy, and provide an urgent route for new impaction, feeding refusal, dehydration or weight loss. The next concrete step is for the treating gastroenterologist to document baseline weight, symptoms and prior endoscopic findings, and schedule the review that determines whether a supervised PPI trial should precede dietary or biologic escalation.